|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
National Institute on Drug Abuse (NIDA) New York State Psychiatric Institute |
| Information provided by: | National Institute on Drug Abuse (NIDA) |
| ClinicalTrials.gov Identifier: | NCT00000273 |
Purpose
The purpose of this study is to evaluate the effects of treatment medications (methadone, buprenorphine, LAAM, naltrexone, naltrexone microcapsules, and methoclocinnamox) on I.V. and smoked heroin self-administration."
| Condition | Intervention | Phase |
|
Heroin Dependence Opioid-Related Disorders Substance-Related Disorders |
Drug: Methadone |
Phase II |
| MedlinePlus related topics: | Heroin |
| ChemIDplus related topics: | Methadone Methadone hydrochloride Diacetylmorphine Diacetylmorphine hydrochloride |
| Study Type: | Interventional |
| Study Design: | Treatment |
| Official Title: | A Laboratory Model for Heroin Abuse Medications |
Eligibility
| Ages Eligible for Study: | 18 Years to 45 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Please contact site for information.
Contacts and Locations| United States, New York | |||||
| Columbia University | |||||
| New York, New York, United States, 10023 | |||||
| National Institute on Drug Abuse (NIDA) |
| New York State Psychiatric Institute |
| Principal Investigator: | Herbert Kleber, M.D. | New York State Psychiatric Institute |
More Information
| Study ID Numbers: | NIDA-09236-8, P50-09236-8 |
| First Received: | September 20, 1999 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00000273 |
| Health Authority: | United States: Federal Government |
|
|
|